| R03AK06 |
Salmeterol, Fluticasone |
Aerivio Spiromax |
Inhalation powder |
50 mcg/500 mcg |
|
1 inhaler (60 doses) |
Teva B.V., Нидерландия |
2 |
UD |
64.54 |
- |
1.418 |
42.54 |
100% |
42.54 |
|
J44.8,J45.0,J45.1 |
НСР-12270/07.04.2017; НСР-15920/15.06.2018; НСР-18913/06.06.2019 |
02.07.2019 |
|
|
Заличен |
15649 |
| R03AK06 |
Salmeterol, Fluticasone |
AirFluSal Forspiro |
Inhalation powder, pre dispensed |
50 mcg/250 mcg/dose - 60 doses |
UD |
1 |
Sandoz d.d., Словения |
2 |
UD |
33.31 |
- |
1.11033 |
33.31 |
100% |
33.31 |
|
J45.0,J45.1 |
НСР-6895/06.08.2015; НСР-9202/05.05.2016; НСР-13499/18.08.2017; КП-39/15.04.2019 и НСР-17268/14.11.2018 |
02.06.2019 |
|
|
Активен |
4060 |
| R03AK06 |
Salmeterol, Fluticasone |
AirFluSal Forspiro |
Inhalation powder, pre dispensed |
50 mcg/500 mcg/ dose-60 doses |
UD |
1 |
Sandoz Pharmaceuticals d.d., Словения |
2 |
UD |
42.54 |
- |
1.418 |
42.54 |
100% |
42.54 |
|
J44.8,J45.0,J45.1 |
НСР-4246/30.07.2014.; НСР-7270/21.10.2015.; КП-33/25.05.2017 и НСР-11769/17.02.2017; НСР-16860/21.09.2018 предварително изпълнение |
02.10.2018 |
|
|
Активен |
3051 |
| R03AK06 |
Salmeterol, Fluticasone |
Salmeterol and fluticasone Cipla |
Pressurised inhalation, suspension |
25 mcg/250 mcg |
|
120 doses |
Cipla (UK) Ltd., Обединено Кралство |
2 |
UD |
43.93 |
- |
0.73217 |
43.93 |
100% |
43.93 |
|
J45.0,J45.1 |
НСР-15801/08.06.2018; корекционно решение НСР-16098/05.07.2018 |
02.10.2018 |
|
|
Активен |
16271 |
| R03AK06 |
Salmeterol, Fluticasone |
Salmeterol and fluticasone Cipla |
Pressurised inhalation, suspension |
25 mcg/125 mcg |
|
120 doses |
Cipla (UK) Ltd., Обединено Кралство |
2 |
UD |
35.4 |
- |
0.59 |
35.4 |
100% |
35.4 |
|
J45.0,J45.1 |
НСР-15801/08.06.2018; корекционно решение НСР-16098/05.07.2018 |
02.10.2018 |
|
|
Активен |
16272 |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder, pre dispensed |
50 mcg/250 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
51.67 |
- |
1.11033 |
33.31 |
100% |
33.31 |
|
J45.0,J45.1 |
№26/04.08.2009; № 67/ 08.04.2010; №37/21,08,2009; НСР-2643/03.02.2014; НСР-4904/22.10.2014; НСР-6675/09.07.2015; НСР-9233/05.05.2016; НСР-10437/29.09.2016; НСР-14681/20.12.2017; НСР-18283/28.03.2019 |
02.06.2019 |
08.09.2012 |
|
Активен |
3331 |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder, pre dispensed |
50 mcg/100 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
37.56 |
- |
1.252 |
37.56 |
100% |
37.56 |
|
J45.0,J45.1 |
№26/04.08.2009; № 67/ 08.04.2010; №37/21,08,2009; НСР-2703/06.02.2014; КП-189/30.04.2015; НСР-6182/08.05.2015; НСР-9233/05.05.2016; НСР-10022/18.08.2016; НСР-14513/23.11.2017; НСР-17834/30.01.2019 |
02.03.2019 |
08.09.2012 |
|
Активен |
3879 |
| R03AK06 |
Salmeterol, Fluticasone |
SERETIDE DISCUS |
Inhalation powder, pre dispensed |
50 mcg/500 mcg/dose - 60 doses |
UD |
1 |
ГлаксоСмитКлайн ЕООД, България |
2 |
UD |
64.54 |
- |
1.418 |
42.54 |
100% |
42.54 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; № 67/ 08.04.2010; №37/21,08,2009; НСР-4601/15.09.2014; НСР-10990/24.11.2016; НСР-15079/23.02.2018 |
02.10.2018 |
08.09.2012 |
|
Активен |
3205 |
| R03AK07 |
Budesonide/Formoterol |
R03AK07 Budesonide/Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK07 |
Budesonide, Formoterol |
AIRBUFO FORSPIRO |
Inhalation powder, pre dispensed |
160 mcg + 4,5 mcg/dose 60 doses |
UD |
2 |
Sandoz Pharmaceuticals d.d., Словения |
4 |
UD |
46.93 |
- |
1.56433 |
46.93 |
100% |
46.93 |
|
J44.8,J45.0,J45.1 |
НСР-19247/18.07.2019; НСР-19373/26.07.2019-Предварително изпълнение |
02.08.2019 |
|
|
Активен |
16618 |
| R03AK07 |
Budesonide, Formoterol |
DuoResp® Spiromax® |
Inhalation powder |
320 mcg/9 mcg/dose - 60 doses |
UD |
1 |
Teva Pharma B.V., Нидерландия |
2 |
UD |
60.19 |
- |
1.56433 |
46.93 |
100% |
46.93 |
не се прилага на лица под 18 години |
J44.8,J45.0,J45.1 |
НСР-4736/02.10.2014; НСР-11067/01.12.2016; НСР-15149/02.03.2018; НСР-18991/13.06.2019 |
02.08.2019 |
|
|
Активен |
4017 |
| R03AK07 |
Budesonide, Formoterol |
DuoResp® Spiromax® |
Inhalation powder |
160 mcg/4,5 mcg/dose - 120 doses |
UD |
1 |
Teva Pharma B.V., Нидерландия |
4 |
UD |
63.12 |
- |
1.56433 |
46.93 |
100% |
46.93 |
не се прилага на лица под 18 години |
J44.8,J45.0,J45.1 |
НСР-4735/02.10.2014; НСР-11068/01.12.2016; НСР-15141/02.03.2018; НСР-18990/13.06.2019 |
02.08.2019 |
|
|
Активен |
4016 |
| R03AK07 |
Budesonide, Formoterol |
SYMBICORT TURBUHALER |
Inhalation powder |
160 mcg/4,5 mcg/dose - 120 doses |
IU |
1 |
Astra Zeneca AB, Швеция |
4 |
UD |
58.7 |
- |
1.56433 |
46.93 |
100% |
46.93 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; №37/21,08,2009; КЦРР-925/04.07.2012 г.КЦРР-473/19.04.2012-КП-180/10.04.2013; НСР-2284/13.01.2014; НСР-4749/02.10.2014 и КП-21/17.02.2015.; НСР-9211/ 05.05.2016; КП-128/03.11.2017 и НСР-13509/18.08.2017; НСР-18105/07.03.2019 |
02.08.2019 |
08.09.2012 |
|
Активен |
3616 |
| R03AK07 |
Budesonide, Formoterol |
SYMBICORT TURBUHALER |
Inhalation powder |
320 mcg/9 mcg/dose - 60 doses |
IU |
1 |
Astra Zeneca AB, Швеция |
2 |
UD |
60.04 |
- |
1.56433 |
46.93 |
100% |
46.93 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; №37/21,08,2009; КЦРР-925/04.07.2012 г.; КЦРР-473/19.04.2012-КП-180/10.04.2013; НСР-2283/13.01.2014; НСР-4749/02.10.2014 и КП-17/17.02.2015.; НСР-9210/ 05.05.2016; КП-129/03.11.2017 и НСР-13510/18.08.2017; НСР-18106/07.03.2019 |
02.08.2019 |
08.09.2012 |
|
Активен |
3615 |
| R03AK07 |
Budesonide, Formoterol |
SYMBICORT TURBUHALER 160/4,5 MCG/INHALATION |
Inhalation powder |
160 mcg/4,5 mcg/dose - 60 doses |
IU |
1 |
Astra Zeneca AB, Швеция |
4 |
UD |
48.6 |
- |
2.37233 |
35.58 |
100% |
35.58 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; №37/21,08,2009; КЦРР-2774/20.03.2013 г.; НСР-6799/23.07.2015. |
16.08.2015 |
08.09.2012 |
|
Заличен |
1818 |
| R03AK07 |
Budesonide/Formoterol |
R03AK07 Budesonide/Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK07 |
Budesonide, Formoterol |
Symbicort |
Pressurised inhalation, suspension |
160 mcg/4,5 mcg - 120 actuations |
|
1 |
Astra Zeneca AB, Швеция |
4 |
UD |
- |
83.2 |
2.77333 |
83.2 |
75% |
62.4 |
|
J44.8 |
НСР-11030/ 25.11.2016 (предварително изпълнение); НСР-13460/11.08.2017; НСР-15431/19.04.2018 |
02.06.2018 |
|
|
Активен |
15485 |
| R03AK08 |
Beclometasone dipropionate/ formoterol fumarate dihydrate |
R03AK08 Beclometasone dipropionate/ formoterol fumarate dihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK08 |
beclometasone, formoterol |
Foster |
Pressurised inhalation, solution |
0,1 mg/0,006 mg - 120 doses |
UD |
1 |
Chiesi Pharmaceuticals GmbH, Австрия |
4 |
UD |
65.78 |
- |
2.18533 |
65.56 |
100% |
65.56 |
|
J44.8,J45.0,J45.1 |
№ 33/21.08.2009; КЦРР-2924/20.03.2013 г; НСР-2384/21.01.2014; НСР-3867/20.06.2014; НСР-4746/02.10.2014; НСР-12738/19.05.2017; НСР-16269/27.07.2018 |
02.01.2019 |
08.09.2012 |
|
Активен |
3218 |
| R03AK08 |
beclometasone, formoterol |
Foster NEXThaler |
Inhalation powder |
100 mcg/6 mcg/dose - 120 doses |
IU |
1 |
Chiesi Pharmaceuticals GmbH, Австрия |
4 |
UD |
65.56 |
- |
2.18533 |
65.56 |
100% |
65.56 |
не се прилага на лица под 18 години |
J44.8,J45.0,J45.1 |
НСР-4734/02.10.2014.; НСР-6412/12.06.2015; НСР-8223/22.02.2016; НСР-10676/21.10.2016 и НСР-11029/25.11.2016 (предварително изпълнение); НСР-13278/20.07.2017; НСР-15354/30.03.2018; НСР-17355/30.11.2018 |
02.01.2019 |
|
|
Активен |
3217 |
| R03AK10 |
Fluticasone furoate/Vilanterol |
R03AK10 Fluticasone furoate/Vilanterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK10 |
Fluticasone furoate, Vilanterol |
Relvar Ellipta |
Inhalation powder, pre dispensed |
184 mcg/22 mcg |
UD |
30 doses |
GlaxoSmithKline (Ireland) Limited, Ирландия |
1 |
UD |
73.22 |
- |
2.44067 |
73.22 |
100% |
73.22 |
J45.0, J45.1- Не се прилага при лица, ненавършили 12 години |
J45.0,J45.1 |
НСР-4582/15.09.2014.; НСР-4697/26.09.2014.; НСР-6381/03.06.2015.; НСР-18241/22.03.2019 |
02.05.2019 |
|
|
Активен |
3176 |
| R03AK10 |
Fluticasone furoate, Vilanterol |
Relvar Ellipta |
Inhalation powder, pre dispensed |
92 mcg/22 mcg |
UD |
30 doses |
GlaxoSmithKline (Ireland) Limited, Ирландия |
1 |
UD |
62.05 |
- |
2.06833 |
62.05 |
100% |
62.05 |
J45.0, J45.1- Не се прилага при лица, ненавършили 12 години |
J44.8,J45.0,J45.1 |
НСР-4581/15.09.2014; НСР-6382/03.06.2015. и КП-360/26.08.2015.; НСР-9363/19.05.2016; НСР-13589/25.08.2017; НСР-15732/25.05.2018; НСР-18154/07.03.2019 |
02.04.2019 |
|
|
Активен |
3177 |
| R03AK11 |
Fluticasone propionate/formoterol fumarate dihydrate |
R03AK11 Fluticasone propionate/formoterol fumarate dihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK11 |
Fluticasone, Formoterol |
Flutiform |
Pressurised inhalation, suspension |
125 mcg/5 mcg (120 впръсквания) |
|
1 |
Mundipharma GmbH, Австрия |
4 |
UD |
66.8 |
- |
2.22667 |
66.8 |
100% |
66.8 |
При възрастни и деца над 12 години |
J45.0,J45.1 |
НСР-3169/07.04.2014.; НСР-5290/ 18.12.2014.; НСР-7184/09.10.2015.; КП-30/26.04.2018 и НСР-15071/23.02.2018; КП-41/25.04.2019 и НСР-17892/07.02.2019 |
02.06.2019 |
|
|
Активен |
3456 |